TABLE 2

Dosimetry Characteristics Derived from Using Reference Protocol

CharacteristicGroup before treatmentGroup after treatment
Reference MTA (GBq)21 (21) ± 8 (6–48)25 (24) ± 9 (6–49)
Bone marrow/lung*95/13103/0
Whole-body residence time (h)31 (27) ± 15 (13–81)22 (20) ± 9 (11–60)
Blood residence time (h)3.2 (2.7) ± 1.4 (1.5–9.9)2.9 (2.6) ± 1.3 (1.2–9.9)
Residence time ratio (τBSWC)0.11 (0.11) ± 0.03 (0.03–0.23)0.13 (0.13) ± 0.02 (0.05–0.19)
Blood uptake at 2 h (%)13.9 (13.9) ± 2.6 (7.2–22.1)14.2 (14.1) ± 2.7 (7.2–22.4)
Blood dose (Gy/GBq)0.11 (0.09) ± 0.05 (0.04–0.34)0.09 (0.08) ± 0.04 (0.04–0.34)
Whole-body retention at 48 h (%)16 (13) ± 10 (2–57)10 (8) ± 8 (1–41)
Contribution of β dose (%)70 (71) ± 7.0 (43–83)74 (74) ± 4.1 (54–83)
  • * Number of patients with MTAs limited by possible bone marrow or lung toxicity.

  • Percentage of β-particle dose to total blood dose.

  • Statistics are provided in the following form: mean (median) ± SD (minimum to maximum).